Editas Medicine EVP, chief scientific officer, sells $13,157 in stock By Investing.com

Linda Burkly, Executive Vice President and Chief Scientific Officer at Editas Medicine, Inc. (), sold 4,928 shares of the company’s common stock on July 28, 2026. The shares were sold at a price of $2.67 per share, totaling approximately $13,157.

The transaction was executed to cover tax withholding obligations resulting from the vesting of restricted stock units on July 24, 2026, according to a footnote in the filing. The sale was carried out pursuant to a durable automatic sales instruction plan adopted by Ms. Burkly on July 3, 2023, and does not represent a discretionary trade. The sale comes as Editas Medicine shares have gained roughly 31% over the past six months, though the stock remains highly volatile with a beta of 2.1.

Following this transaction, Ms. Burkly beneficially owns 62,369 shares of Editas Medicine common stock directly. According to InvestingPro analysis, the stock currently trades slightly above its Fair Value and carries a “WEAK” financial health score. Investors can access 12 additional InvestingPro Tips for deeper insights into the company’s prospects.

In other recent news, Editas Medicine announced a public offering of 55,555,556 shares of common stock and accompanying warrants, priced at $2.25 per share. This offering is expected to raise approximately $125 million in gross proceeds before underwriting discounts and commissions. Additionally, Editas Medicine presented promising preclinical data for its gene editing treatment candidate, EDIT-401, at a recent conference, demonstrating significant reductions in LDL cholesterol and other lipoproteins in non-human primates. In corporate governance developments, the company held its 2026 Annual Meeting of Stockholders, where Bernadette Connaughton and Elliott Levy, M.D., were elected as Class I directors. The stock offering announcement led to a decline in Editas Medicine shares, as reported. Cantor and Wells Fargo Securities are managing the stock offering. These developments highlight the company’s ongoing efforts in both financial and scientific advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.